PubRank

Mutations in SETD2 cause a novel overgrowth condition.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMID 24852293)

Published in J Med Genet on May 22, 2014

Authors

Armelle Luscan1, Ingrid Laurendeau1, Valérie Malan2, Christine Francannet3, Sylvie Odent4, Fabienne Giuliano5, Didier Lacombe6, Renaud Touraine7, Michel Vidaud1, Eric Pasmant1, Valérie Cormier-Daire8

Author Affiliations

1: EA7331, Université Paris Descartes, Sorbonne Paris Cité, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France Service de Biochimie et de Génétique Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
2: Service d'Histo-Embryo-Cytogénétique, Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Paris, France.
3: Service de Génétique Médicale, CHU Estaing, Clermont-Ferrand, France.
4: Université de Rennes 1, CNRS UMR6290, Service de Génétique Clinique, CHU Hôpital Sud, Rennes, France.
5: Service de Génétique Médicale, CHU Hôpital l'Archet 2, Nice, France.
6: Service de Génétique Médicale, CHU de Bordeaux et EA4576, Université de Bordeaux, Bordeaux, France.
7: Service de Génétique, CHU de Saint-Etienne, hôpital Nord, Saint-Etienne, France.
8: INSERM UMR_1163, Département de génétique, Université Paris Descartes Sorbonne Paris Cité, Institut Imagine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.

Articles citing this ↘

Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. Nat Neurosci (2016) 1.07

Brief Report: SETD2 Mutation in a Child with Autism, Intellectual Disabilities and Epilepsy. J Autism Dev Disord (2015) 0.87

NSD1 mutations generate a genome-wide DNA methylation signature. Nat Commun (2015) 0.86

Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun (2016) 0.85

A novel mutation in EED associated with overgrowth. J Hum Genet (2015) 0.79

SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget (2016) 0.78

H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. Future Med Chem (2016) 0.76

A New Case of an Extremely Rare 3p21.31 Interstitial Deletion. Mol Syndromol (2016) 0.75

19p13.2 Microdeletion including NFIX associated with overgrowth and intellectual disability suggestive of Malan syndrome. Mol Cytogenet (2016) 0.75

Articles by these authors ⇆

Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations. Am J Med Genet A (2016) 0.76